1
|
Lloyd RV, Buehler D and Khanafshar E:
Papillary thyroid carcinoma variants. Head Neck Pathol. 5:51–56.
2011. View Article : Google Scholar
|
2
|
Singh A, Butuc R and Lopez R: Metastatic
papillary thyroid carcinoma with absence of tumor focus in thyroid
gland. Am J Case Rep. 14:73–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Silver CE, Owen RP, Rodrigo JP, et al:
Aggressive variants of papillary thyroid carcinoma. Head Neck.
33:1052–1059. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Voutilainen PE, Multanen MM, Leppaniemi
AK, et al: Prognosis after lymph node recurrence in papillary
thyroid carcinoma depends on age. Thyroid. 11:953–957. 2001.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Chou CK, Chen RF, Chou FF, et al: miR-146b
is highly expressed in adult papillary thyroid carcinomas with high
risk features including extrathyroidal invasion and the BRAF(V600E)
mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Chen PS, Su JL and Hung MC: Dysregulation
of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
|
7
|
O’Day E and Lal A: MicroRNAs and their
target gene networks in breast cancer. Breast Cancer Res.
12:2012010.
|
8
|
Carvalho J, van Grieken NC, Pereira PM, et
al: Lack of microRNA-101 causes E-cadherin functional deregulation
through EZH2 up-regulation in intestinal gastric cancer. J Pathol.
228:31–44. 2012.PubMed/NCBI
|
9
|
Chandramouli A, Onyeagucha BC,
Mercado-Pimentel ME, et al: MicroRNA-101 (miR-101)
post-transcriptionally regulates the expression of EP4 receptor in
colon cancers. Cancer Biol Ther. 13:175–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wang R, Wang HB, Hao CJ, et al: MiR-101 is
involved in human breast carcinogenesis by targeting Stathmin1.
PLoS One. 7:e461732012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fritz G, Just I and Kaina B: Rho GTPases
are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Silva AL, Carmo F and Bugalho MJ: RAC1b
overexpression in papillary thyroid carcinoma: a role to unravel.
Eur J Endocrinol. 168:795–804. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lewis-Saravalli S, Campbell S and Claing
A: ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231
invasive breast cancer cells. Cell Signal. 25:1813–1819. 2013.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Guan H, Wei G, Wu J, et al:
Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to
promote invasion and progression of thyroid cancer. J Clin
Endocrinol Metab. 98:E1334–El1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Liu D, Xia P, Diao D, et al: MiRNA-429
suppresses the growth of gastric cancer cells in vitro. J Biomed
Res. 26:389–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar
|
18
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Liu X, He M, Hou Y, et al: Expression
profiles of microRNAs and their target genes in papillary thyroid
carcinoma. Oncol Rep. 29:1415–1420. 2013.PubMed/NCBI
|
20
|
Wu YJ, Tang Y, Li ZF, Li Z, Zhao Y, Wu ZJ
and Su Q: Expression and significance of Rac1, Pak1 and Rock1 in
gastric carcinoma. Asia Pac J Clin Oncol. Jan 8–2013.(Epub ahead of
print). View Article : Google Scholar
|
21
|
Schnelzer A, Prechtel D, Knaus U, et al:
Rac1 in human breast cancer: overexpression, mutation analysis, and
characterization of a new isoform, Rac1b. Oncogene. 19:3013–3020.
2000. View Article : Google Scholar : PubMed/NCBI
|
22
|
Jordan P, Brazao R, Boavida MG, Gespach C
and Chastre E: Cloning of a novel human Rac1b splice variant with
increased expression in colorectal tumors. Oncogene. 18:6835–6839.
1999. View Article : Google Scholar : PubMed/NCBI
|
23
|
Liu Y, Wang Y, Zhang Y, et al: Abnormal
expression of p120-catenin, E-cadherin, and small GTPases is
significantly associated with malignant phenotype of human lung
cancer. Lung Cancer. 63:375–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Bosco EE, Mulloy JC and Zheng Y: Rac1
GTPase: a ‘Rac’ of all trades. Cell Mol Life Sci. 66:370–374.
2009.
|
25
|
Sempere LF: Integrating contextual miRNA
and protein signatures for diagnostic and treatment decisions in
cancer. Expert Rev Mol Diagn. 11:813–827. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Swarbrick A, Woods SL, Shaw A, et al:
miR-380-5p represses p53 to control cellular survival and is
associated with poor outcome in MYCN-amplified neuroblastoma. Nat
Med. 16:1134–1140. 2010. View
Article : Google Scholar : PubMed/NCBI
|
27
|
Cairo S, Wang Y, de Reynies A, et al: Stem
cell-like micro-RNA signature driven by Myc in aggressive liver
cancer. Proc Natl Acad Sci USA. 107:20471–20476. 2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
Cho WC: MicroRNAs in cancer - from
research to therapy. Biochim Biophys Acta. 1805:209–217.
2010.PubMed/NCBI
|
29
|
Wahid F, Shehzad A, Khan T and Kim YY:
MicroRNAs: synthesis, mechanism, function, and recent clinical
trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|